3Helix CHP Indication: Myocardial Infarction
Map Collagen Damage in Myocardial Infarction
Introduction
3Helix Collagen Hybridizing Peptides (CHPs) are short peptides that selectively target damaged and remodeling collagen for applications in therapeutics, cosmetics, drug delivery systems, and life science tools.
Summary
Myocardial Infarction (MI) Indication: With Collagen Hybridizing Peptides (CHPs) you can visualize collagen damage from 3 days post-MI onward, and observe its direct correlation to macrophage infiltration.
Indication Note
Assess cardiac remodeling after Myocardial Infarction with Collagen Hybridizing Peptides (CHPs).
Myocardial Infarction (MI) initiates a complex remodeling process involving significant collagen damage. Accurately quantifying damaged collagen in cardiac tissue samples is essential for understanding patient outcomes and assessing treatment response.
- Visualize collagen damage as early as 3 days post-MI, enabling the tracking of early-stage remodeling and inflammatory responses
- Correlate collagen damage directly with macrophage infiltration (CD68 staining), providing a detailed view of the inflammatory contribution to remodeling.
- Provide quantifiable data, consistent with MMP activity studies, for use as a reliable secondary endpoint in clinical trials assessing post-MI recovery.
Ilex Life Sciences LLC is an authorized distributor of CHP products manufactured by 3Helix, Inc.